atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

atai Life Sciences (ATAI) received FDA approval for a study to investigate how its R-ketamine compound interacts with other drugs.

PDF of article